Dolutegravir plasma levels after gastric bypass surgery
Authors:
- Manuel BattegayMBManuel Battegay
- Catia MarzoliniCMCatia Marzolini
- 24 April 2017
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 31 (7) , 1052-1054
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjectsThe Journal of Clinical Pharmacology, 2014
- Tenofovir, Emtricitabine, and Darunavir/Ritonavir Pharmacokinetics in an HIV-Infected Patient After Roux-en-Y Gastric Bypass SurgeryAnnals of Pharmacotherapy, 2014
- Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in HumansAntimicrobial Agents and Chemotherapy, 2013
- Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor DolutegravirClinical Pharmacokinetics, 2013
- A validated assay by liquid chromatography–tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patientsJournal of Mass Spectrometry, 2013
- Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With RifabutinJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Gastric bypass reduces fat intake and preferenceAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2011
- Bariatric Surgery Outcomes in HIV-Infected Subjects: A Case SeriesAIDS Patient Care and STDs, 2010
- Increasing Rates of Obesity among HIV-Infected Persons during the HIV EpidemicPLOS ONE, 2010
- Medication and nutrient administration considerations after bariatric surgeryAmerican Journal of Health-System Pharmacy, 2006